Evestia Clinical——EMAS Pharma的新品牌标识——今天作为市场领先的制药研究专家推出，专注于肿瘤学和罕见病的临床试验-动脉网

Evestia Clinical - the new brand identity for EMAS Pharma - launches today as a market leading pharmaceutical research specialist focussed on Clinical Trials in Oncology and Rare Diseases

CISION 等信源发布 2025-03-20 23:32



可切换为仅中文







LETCHWORTH GARDEN CITY,

莱奇沃思花园城市，

England

英格兰

，

March 20, 2025

2025年3月20日

/PRNewswire/ -- Evestia Clinical has today been announced as the new identity of EMAS Pharma, as it sets its sights on rapid growth as a provider of clinical research in oncology and rare diseases globally.

/PRNewswire/ -- Evestia Clinical今天被宣布为EMAS Pharma的新身份，其目标是作为全球肿瘤学和罕见病临床研究的提供商实现快速增长。

继续阅读

Evestia Clinical - the new brand identity for EMAS Pharma - launches today as a market leading pharmaceutical research specialist focussed on Clinical Trials in Oncology and Rare Diseases

Evestia Clinical——EMAS Pharma的新品牌形象——今天作为市场领先的专注于肿瘤学和罕见病临床试验的制药研究专家推出。

Evestia Clinical is backed by Kester Capital and headed by a strong leadership team including

Evestia Clinical由Kester Capital支持，并由一个强大的领导团队领导，包括

Richard Barfield

理查德·巴菲尔德

(Chairman),

（主席），

Lewis Cameron

刘易斯·卡梅伦

(CEO),

（首席执行官），

Roy Ovel

罗伊·奥维尔

(CCO), and

（CCO），以及

Carl Hvass

卡尔·胡瓦斯

(CFO). The name Evestia is inspired by the company's mission to pioneer transformational advancements in clinical research. It represents a commitment to making a lasting imprint in the industry by driving meaningful progress in oncology and rare disease trials and strengthening partnerships with biotech companies..

（首席财务官）。Evestia 这个名字的灵感来源于公司致力于在临床研究领域开创变革性进展的使命。它代表着一种通过推动肿瘤学和罕见病试验的实质性进展，并加强与生物技术公司的合作，从而在行业内留下持久印记的决心。

'The launch of Evestia Clinical marks an exciting new chapter in our journey,' said

“Evestia临床试验的启动标志着我们旅程中令人兴奋的新篇章，”表示

Richard Barfield

理查德·巴菲尔德

, Chairman of Evestia Clinical.

，Evestia临床公司董事长。

'Our leadership team has a proven track record of driving growth in the CRO sector, and with the support of Kester Capital, we are well-positioned to accelerate our expansion, strengthen our service offerings, and broaden our global reach. We are building a world-class platform that will deliver exceptional value to our biotech clients..

“我们的领导团队在CRO领域有着推动增长的成功记录，在Kester Capital的支持下，我们有能力加速扩张、强化服务产品并扩大全球影响力。我们正在打造一个世界级的平台，将为我们的生物技术客户提供卓越的价值。”

'Our new identity reaffirms our focus on delivering high-quality clinical trials in oncology and rare diseases, where there is an urgent need for innovation and speed. We are firmly placed to support biotech companies in bringing life-changing therapies to market.'

“我们的新身份重申了我们专注于在肿瘤学和罕见疾病领域开展高质量临床试验的承诺，这些领域对创新和速度有着迫切的需求。我们有能力坚定地支持生物技术公司，将改变生命的疗法推向市场。”

Evestia Clinical's mission is clear: To empower biotech innovators by providing expert-driven, agile, and personalized clinical research solutions - accelerating the development of life-changing therapies with confidence and care. This mission reflects its unwavering commitment to excellence, integrity, and innovation in the pursuit of advancing healthcare worldwide..

Evestia Clinical的使命很明确：通过提供专家驱动、灵活且个性化的临床研究解决方案，赋能生物技术革新者——以信心和关怀加速改变生命的疗法的开发。这一使命反映了其在推进全球医疗保健过程中对卓越、诚信和创新的坚定承诺。

'We are committed to providing our clients with the most effective and adaptive clinical trial solutions,' said

“我们致力于为客户提供最有效和最具适应性的临床试验解决方案，”

Lewis Cameron

刘易斯·卡梅伦

, CEO. 'This transformation aligns with our long-term vision of being the preferred CRO partner for biotech companies focused on complex, high-impact research areas.'

，首席执行官。“这一转型符合我们成为专注于复杂、高影响力研究领域的生物技术公司首选CRO合作伙伴的长期愿景。”

Adam Maidment, Managing Partner at Kester Capital, commented: 'Kester has been investing in CROs for over a decade, and we see Evestia Clinical as a highly strategic platform in a dynamic and fast-growing global market. We are delighted to be partnering once again with Richard, Lewis, Roy, Carl, and the existing Evestia Clinical team to support the next phase of growth - both organically and through acquisition as they continue to drive innovation in clinical research.'.

凯斯特资本 (Kester Capital) 管理合伙人亚当·梅德门特 (Adam Maidment) 表示：“凯斯特已投资合同研究组织 (CRO) 十余年，我们认为依维斯蒂亚临床 (Evestia Clinical) 在这个充满活力且快速增长的全球市场中是一个极具战略意义的平台。我们很高兴再次与理查德、刘易斯、罗伊、卡尔以及现有的依维斯蒂亚临床团队合作，支持公司下一阶段的增长——无论是通过有机增长还是收购，因为他们会继续推动临床研究领域的创新。”

About Evestia Clinical

关于Evestia临床

Evestia Clinical is a leading CRO specializing in clinical trials for oncology and rare diseases. With a commitment to scientific excellence, innovation, and patient-centric research, Evestia Clinical partners with biotech companies to accelerate the development of life-saving therapies. Backed by Kester Capital, Evestia Clinical is dedicated to advancing healthcare through cutting-edge clinical research..

Evestia Clinical是一家领先的合同研究组织（CRO），专注于肿瘤学和罕见病的临床试验。秉承科学卓越、创新和以患者为中心的研究理念，Evestia Clinical与生物技术公司合作，加速救命疗法的开发。在Kester Capital的支持下，Evestia Clinical致力于通过前沿的临床研究推动医疗保健的发展。

Evestia Clinical's vision is to be the market-leading clinical service partner for biotechs and beyond - fuelling medical breakthroughs to improve global health within a culture that values, inspires, and empowers.

Evestia Clinical 的愿景是成为生物技术领域及更广泛范围内的市场领先临床服务合作伙伴——推动医学突破，改善全球健康，营造重视、激励和赋权的文化。

Photo:

照片：

https://mma.prnewswire.com/media/2646471/Evestia_Clinical.jpg

SOURCE Evestia Clinical

来源 Evestia 临床

WANT YOUR COMPANY'S NEWS

想要你公司的新闻吗

FEATURED ON PRNEWSWIRE.COM?

刊登在PRNEWSWIRE.COM上？

440k+

44万+